OncLive SOSS

Myelodysplastic Syndromes (MDS): Recent Updates and Evolving Treatment Paradigms - Episode 12

Luspatercept for Lower-Risk MDS: Data From the COMMANDS Trial

July 28, 2023

Rami Komrokji, MD, Andrew Brunner, MD, Hetty Carraway, MD, Yazan Madanat, MD, Amer Zeidan, MBBS, MHS

Rami Komrokji, MD, summarizes data presented at ASCO 2023 from the COMMANDS trial on the role of luspatercept in lower-risk MDS.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Diagnosing Myelodysplastic Syndromes (MDS)

EP. 2: Risk Stratification of MDS

EP. 3: First-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia

EP. 4: Initiating Treatment for Lower-Risk MDS With Symptomatic Anemia

EP. 5: Monitoring Treatment With ESAs for Lower-Risk MDS With Symptomatic Anemia

EP. 6: Second-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia

EP. 7: Patient Profile: A 75-Year-Old Man With Lower-Risk MDS and Symptomatic Anemia

EP. 8: Treatment Approaches for Lower-Risk MDS With Symptomatic Anemia

EP. 9: Patient Profile: A 79-Year-Old Man With Lower-Risk MDS and a KRAS Mutation

EP. 10: Treatment Approaches for Lower-Risk MDS With RAS Mutations

EP. 11: ESA Outcomes by SF3B1 Mutation Status in Lower-Risk MDS

EP. 12: Luspatercept for Lower-Risk MDS: Data From the COMMANDS Trial

EP. 13: Imetelstat for Lower-Risk MDS: Data From the IMerge Trial

EP. 14: Oral HMAs in Lower-Risk MDS Treatment

EP. 15: IRAK1 and IRAK4 Inhibitors for the Treatment of Lower-Risk MDS

EP. 16: Key Trials in the Treatment of Higher-Risk MDS

EP. 17: Final Thoughts on Recent Data Updates in MDS

x